- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05211245
Comparative Evaluation of Continuous and Pulse Mode of Ultrasound Therapy in Myalgia of Maxillofacial Region
March 13, 2023 updated by: Postgraduate Institute of Dental Sciences Rohtak
Pain and trismus caused by Myalgia in masticatory muscles are one of the prime concerns for the patients.
Various studies have been performed using US therapy for myofascial pain syndrome of head & neck region.
US is a non-invasive frequently used physical agent which increase blood flow in tissues and collagen fibers ability to grow, & reduce muscle spasm with its thermal effect.
It is difficult to imply the results of studies performed in muscles of other regions of body to the maxillofacial region because of the superficial placement of these muscles.US is being frequently used for myofascial pain, but there is an absence of a consensus regarding the frequency and mode of administration available in literature for administration of this therapy in maxillofacial region.
Therefore, the present study has been designed to compare the therapeutic effect of two modes of US i.e., continuous and pulsed at 3 MHz frequency
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Pain and trismus caused by Myalgia in masticatory muscles are one of the prime concerns for the patients.
There are limited number of studies in the literature that have evaluated therapeutic ultrasound for the management of Myalgia of maxillofacial region.
Various studies have been performed, evaluating the treatment of myofascial pain with trigger point in other parts of body including neck region using ultrasound, but not all patient of myalgia present with trigger point.
The most frequently used ultrasound frequencies are 1 and 3MHz. 1 MHz has more penetrating power as compared to 3MHz.
Masticatory muscles being superficial in location need less penetrating waves as compared to other muscles.
The ultrasound can be applied in a continuous or pulsed manner.
There are studies supporting the fact that Continuous ultrasound therapy is more efficient in reducing myofascial pain syndrome of trapezius muscle at rest because it produces a heating effect in the muscles, that help in breaking the spasm.
On the other hand, the pulsed mode, produces more of penetrating effect and acts on the gas bubbles of the soft tissues, thereby decreasing the inflammation.
However, the two methods have not yet been compared in maxillofacial muscles.
Therefore, this study aims to compare the outcome of therapeutic Ultrasound administered at 3MHz frequency in continuous & pulse modes in myalgia of maxillofacial region
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Haryana
-
Rohtak, Haryana, India, 124001
- PGIDS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients diagnosed with myalgia within orofacial muscle as per DC/TMD (Ia and Ib)
- Patient's consent for participation in this study.
Exclusion Criteria:
- Patients with epilepsy/seizures
- Patients with radiographic changes suggestive of pathological conditions of temporomandibular joint (TMJ).
- Patients with undiagnosed orofacial pain
- Any sort of skin lesion at the site where electrode is to be placed.
- Therapeutic ultrasound must not be applied over areas of impaired circulation, ischemic areas, or areas having sensory deficit.
- Sites of active infection
- Patients with metal prosthesis
- Patients with Becks depression score >25 will be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Pulse mode
Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central & peripheral sensitization.
The non-thermal effect of US can be explain by frequency resonance theory which states that the proteins in these structures absorbs mechanical energy thus altering the structure & function, finally resulting in stimulation of phagocytosis, increase number of free radicals, increase cell membrane permeability, cellular proliferation &acceleration of fibrinolysis
|
Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz).
Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain & muscle spasm by altering nerve conduction velocity & changes in cell membrane permeability along with increased rate of tissue repair & wound healing.There are two main types of ultrasound therapy: thermal and mechanical.
Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons & joint capsules, thus leading to decrease in the pain & muscle spasm, stiffness of the joint & temporary increase in the blood flow.
Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central & peripheral sensitization.
|
|
Active Comparator: Continous mode
Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons & joint capsules, thus leading to decrease in the pain & muscle spasm, stiffness of the joint & temporary increase in the blood flow.
|
Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz).
Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain & muscle spasm by altering nerve conduction velocity & changes in cell membrane permeability along with increased rate of tissue repair & wound healing.There are two main types of ultrasound therapy: thermal and mechanical.
Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons & joint capsules, thus leading to decrease in the pain & muscle spasm, stiffness of the joint & temporary increase in the blood flow.
Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central & peripheral sensitization.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To evaluate the intensity of pain in each group
Time Frame: Base line
|
Visual Analog Scale (VAS) 0n a scale of 0-10
|
Base line
|
|
To evaluate the intensity of pain in each group
Time Frame: 2 weeks
|
Visual Analog Scale (VAS) 0n a scale of 0-10
|
2 weeks
|
|
To evaluate the intensity of pain in each group
Time Frame: 4weeks
|
Visual Analog Scale (VAS) 0n a scale of 0-10
|
4weeks
|
|
To evaluate the intensity of pain in each group
Time Frame: 6 weeks
|
Visual Analog Scale (VAS) 0n a scale of 0-10
|
6 weeks
|
|
To evaluate the intensity of pain in each group
Time Frame: 3 months
|
Visual Analog Scale (VAS) 0n a scale of 0-10
|
3 months
|
|
To assess pressure pain sensitivity of muscles in the two groups.
Time Frame: Base line
|
Algometer
|
Base line
|
|
To assess pressure pain sensitivity of muscles in the two groups.
Time Frame: 2 weeks
|
Algometer
|
2 weeks
|
|
To assess pressure pain sensitivity of muscles in the two groups.
Time Frame: 4 weeks
|
Algometer
|
4 weeks
|
|
To assess pressure pain sensitivity of muscles in the two groups.
Time Frame: 6 weeks
|
Algometer
|
6 weeks
|
|
To assess pressure pain sensitivity of muscles in the two groups.
Time Frame: 3 months
|
Algometer
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To evaluate the maximal mouth opening and functional movements
Time Frame: Base line
|
Digital Vernier calliper
|
Base line
|
|
To evaluate the maximal mouth opening and functional movements
Time Frame: 2 weeks
|
Digital Vernier calliper
|
2 weeks
|
|
To evaluate the maximal mouth opening and functional movements
Time Frame: Base line ,2 weeks,4 weeks ,6 weeks, 3 months post treatment
|
Digital Vernier calliper
|
Base line ,2 weeks,4 weeks ,6 weeks, 3 months post treatment
|
|
To evaluate patient psychological status
Time Frame: Base line ,2 weeks,4 weeks ,6 weeks, 3 months post treatment
|
Beck depression inventory
|
Base line ,2 weeks,4 weeks ,6 weeks, 3 months post treatment
|
|
To evaluate quality of life
Time Frame: Base line ,2 weeks,4 weeks ,6 weeks, 3 months post treatment
|
Oral Health Impact Profile (OHIP 14)
|
Base line ,2 weeks,4 weeks ,6 weeks, 3 months post treatment
|
|
To assess the need for pain medication
Time Frame: Base line ,2 weeks,4 weeks ,6 weeks, 3 months post treatment
|
number of medication needed
|
Base line ,2 weeks,4 weeks ,6 weeks, 3 months post treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Dr. Ambika Gupta, MDS, oral medicine & radiology,PGIDS
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2021
Primary Completion (Actual)
October 15, 2022
Study Completion (Actual)
October 15, 2022
Study Registration Dates
First Submitted
August 12, 2021
First Submitted That Met QC Criteria
January 23, 2022
First Posted (Actual)
January 27, 2022
Study Record Updates
Last Update Posted (Actual)
March 14, 2023
Last Update Submitted That Met QC Criteria
March 13, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Dr.Bhawna Saini
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.